198 related articles for article (PubMed ID: 27883367)
1. A drop in the circulating concentrations of soluble receptor for advanced glycation end products is associated with seroconversion to autoantibody positivity but not with subsequent progression to clinical disease in children en route to type 1 diabetes.
Salonen KM; Ryhänen SJ; Forbes JM; Härkönen T; Ilonen J; Simell O; Veijola R; Groop PH; Knip M
Diabetes Metab Res Rev; 2017 May; 33(4):. PubMed ID: 27883367
[TBL] [Abstract][Full Text] [Related]
2. Decrease in circulating concentrations of soluble receptors for advanced glycation end products at the time of seroconversion to autoantibody positivity in children with prediabetes.
Salonen KM; Ryhänen SJ; Forbes JM; Borg DJ; Härkönen T; Ilonen J; Simell O; Veijola R; Groop PH; Knip M
Diabetes Care; 2015 Apr; 38(4):665-70. PubMed ID: 25573878
[TBL] [Abstract][Full Text] [Related]
3. Higher levels of the soluble receptor for advanced glycation end products and lower levels of the extracellular newly identified receptor for advanced glycation end products were associated with lipid-lowering drugs in patients with type 1 diabetes: a comparative cross-sectional study.
Melin EO; Dereke J; Hillman M
Lipids Health Dis; 2020 Oct; 19(1):223. PubMed ID: 33054750
[TBL] [Abstract][Full Text] [Related]
4. Association between serum levels of the soluble receptor (sRAGE) for advanced glycation endproducts (AGEs) and their receptor (RAGE) in peripheral blood mononuclear cells of children with type 1 diabetes mellitus.
Dettoraki A; Gil AP; Spiliotis BE
J Pediatr Endocrinol Metab; 2009 Oct; 22(10):895-904. PubMed ID: 20020577
[TBL] [Abstract][Full Text] [Related]
5. Circulating concentrations of soluble receptor for AGE are associated with age and AGER gene polymorphisms in children with newly diagnosed type 1 diabetes.
Salonen KM; Ryhänen SJ; Forbes JM; Härkönen T; Ilonen J; Laine AP; Groop PH; Knip M;
Diabetes Care; 2014 Jul; 37(7):1975-81. PubMed ID: 24742661
[TBL] [Abstract][Full Text] [Related]
6. Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk.
Parikka V; Näntö-Salonen K; Saarinen M; Simell T; Ilonen J; Hyöty H; Veijola R; Knip M; Simell O
Diabetologia; 2012 Jul; 55(7):1926-36. PubMed ID: 22441569
[TBL] [Abstract][Full Text] [Related]
7. Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes.
Yu Y; Hanssen KF; Kalyanaraman V; Chirindel A; Jenkins AJ; Nankervis AJ; Torjesen PA; Scholz H; Henriksen T; Lorentzen B; Garg SK; Menard MK; Hammad SM; Scardo JA; Stanley JR; Wu M; Basu A; Aston CE; Lyons TJ
BJOG; 2012 Nov; 119(12):1512-20. PubMed ID: 22900949
[TBL] [Abstract][Full Text] [Related]
8. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.
Yamagishi S; Adachi H; Nakamura K; Matsui T; Jinnouchi Y; Takenaka K; Takeuchi M; Enomoto M; Furuki K; Hino A; Shigeto Y; Imaizumi T
Metabolism; 2006 Sep; 55(9):1227-31. PubMed ID: 16919543
[TBL] [Abstract][Full Text] [Related]
9. A strategy to find gene combinations that identify children who progress rapidly to type 1 diabetes after islet autoantibody seroconversion.
Bonifacio E; Krumsiek J; Winkler C; Theis FJ; Ziegler AG
Acta Diabetol; 2014; 51(3):403-11. PubMed ID: 24249616
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
[TBL] [Abstract][Full Text] [Related]
11. Soluble adhesion molecules in young children with signs of beta-cell autoimmunity--prospective follow-up from birth.
Toivonen AM; Kimpimäki T; Kupila A; Korhonen S; Hyöty H; Virtanen SM; Ilonen J; Simell O; Knip M
Diabetes Metab Res Rev; 2006; 22(3):176-83. PubMed ID: 16270299
[TBL] [Abstract][Full Text] [Related]
12. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).
Lam JK; Wang Y; Shiu SW; Wong Y; Betteridge DJ; Tan KC
Diabet Med; 2013 Jun; 30(6):702-9. PubMed ID: 23432638
[TBL] [Abstract][Full Text] [Related]
13. Neonatal and infant beta cell hormone concentrations in relation to type 1 diabetes risk.
Stumpp C; Beyerlein A; Ziegler AG; Bonifacio E
Pediatr Diabetes; 2014 Nov; 15(7):528-33. PubMed ID: 24552441
[TBL] [Abstract][Full Text] [Related]
14. Elevated endogenous secretory receptor for advanced glycation end products (esRAGE) levels are associated with circulating soluble RAGE levels in diabetic children.
Saito R; Araki S; Yamamoto Y; Kusuhara K
J Pediatr Endocrinol Metab; 2017 Jan; 30(1):63-69. PubMed ID: 27941172
[TBL] [Abstract][Full Text] [Related]
15. Circulating Ligands of the Receptor for Advanced Glycation End Products and the Soluble Form of the Receptor Modulate Cardiovascular Cell Apoptosis in Diabetes.
Tsoporis JN; Hatziagelaki E; Gupta S; Izhar S; Salpeas V; Tsiavou A; Rigopoulos AG; Triantafyllis AS; Marshall JC; Parker TG; Rizos IK
Molecules; 2020 Nov; 25(22):. PubMed ID: 33182705
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes.
Nakamura K; Yamagishi S; Adachi H; Kurita-Nakamura Y; Matsui T; Yoshida T; Imaizumi T
Mol Med; 2007; 13(3-4):185-9. PubMed ID: 17592553
[TBL] [Abstract][Full Text] [Related]
17. Advanced glycation end products as environmental risk factors for the development of type 1 diabetes.
Yap FY; Kantharidis P; Coughlan MT; Slattery R; Forbes JM
Curr Drug Targets; 2012 Apr; 13(4):526-40. PubMed ID: 22250649
[TBL] [Abstract][Full Text] [Related]
18. Dietary protein intake and circulating advanced glycation end product/receptor for advanced glycation end product concentrations in the Health, Aging, and Body Composition Study.
Brinkley TE; Semba RD; Kritchevsky SB; Houston DK;
Am J Clin Nutr; 2020 Dec; 112(6):1558-1565. PubMed ID: 33301008
[TBL] [Abstract][Full Text] [Related]
19. Soluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up study.
Heier M; Margeirsdottir HD; Gaarder M; Stensæth KH; Brunborg C; Torjesen PA; Seljeflot I; Hanssen KF; Dahl-Jørgensen K
Cardiovasc Diabetol; 2015 Sep; 14():126. PubMed ID: 26408307
[TBL] [Abstract][Full Text] [Related]
20. Soluble form of receptor for advanced glycation end-products (sRAGE): do sRAGE ligands or anti-sRAGE auto-antibodies interfere with sRAGE quantification?
Lorenzi R; Grossin N; Lambert M; Daroux M; Adjoutah Z; Flahaut C; Jacolot P; Tessier FJ; Lefranc D; Desremaux P; Dubucquoi S; Boulanger E
Ann Clin Biochem; 2014 Mar; 51(Pt 2):248-57. PubMed ID: 23982266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
